David Kim
@Paradigm Biocapital Advisors Lp
Latest period2024 - Q3ReportedManaged Assets$2.956BTotal holdings31
Assets growth rate13.13%Assets growth rate (2-Q avg)2.56%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Paradigm Biocapital Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 31 positions.
Assets under management
The assets under management (AUM) of Paradigm Biocapital Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.956B in assets, with a quarterly growth rate of 13.13% and a 2-quarter average growth rate of 2.56%. The portfolio is managed by David Kim, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
VERAVera Therapeutics Inc
| 1.65% | $48.481M 1.097M shares@ $44.2 avg price | New Position |
MLTXMoonlake Immunotherapeutics
| 1.59% | $46.965M 931,480 shares@ $50.43 avg price | New Position |
BGNEBeigene Ltd
| 1.53% | $44.977M 200,336 shares@ $224.51 avg price | New Position |
SYRESpyre Therapeutics Inc
| 1.27% | $37.28M 1.268M shares@ $29.41 avg price | New Position |
PLRXPliant Therapeutics Inc
| 1.18% | $34.801M 3.104M shares@ $11.21 avg price | New Position |
KROSKeros Therapeutics Inc
| 1.04% | $30.489M 525,037 shares@ $58.08 avg price | New Position |
ORKAOruka Therapeutics Inc
| 0.6% | $17.639M 719,660 shares@ $24.52 avg price | New Position |